E. Pfanner
About
E. Pfanner is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology.
According to data from OpenAlex, E. Pfanner has authored 28 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 7 papers in Hepatology. Recurrent topics in E. Pfanner's work include Colorectal Cancer Treatments and Studies (19 papers), Cancer Treatment and Pharmacology (15 papers) and Hepatocellular Carcinoma Treatment and Prognosis (7 papers). E. Pfanner is often cited by papers focused on Colorectal Cancer Treatments and Studies (19 papers), Cancer Treatment and Pharmacology (15 papers) and Hepatocellular Carcinoma Treatment and Prognosis (7 papers). E. Pfanner collaborates with scholars based in Italy, Switzerland and India. E. Pfanner's co-authors include Alfredo Falcone, Gianluca Masi, I. Brunetti, Giacomo Allegrini, Sergio Ricci, M. Andreuccetti, V. Picone, Laura Fanchini, W. Evangelista and Luisa Fioretto and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Oncology.
In The Last Decade
E. Pfanner
28 papers receiving 1.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| E. Pfanner Italy | 12 | 1.3k | 674 | 470 | 347 | 187 | 28 | 1.5k | ||
| M. Andreuccetti Italy | 14 | 1.5k 1.1× | 841 1.2× | 563 1.2× | 374 1.1× | 209 1.1× | 28 | 1.8k | ||
| H. Kröning Germany | 13 | 1.0k 0.8× | 231 0.3× | 592 1.3× | 254 0.7× | 179 1.0× | 26 | 1.5k | ||
| S. Vitello Italy | 7 | 1.0k 0.8× | 506 0.8× | 405 0.9× | 253 0.7× | 83 0.4× | 11 | 1.1k | ||
| Yousif Abubakr United States | 6 | 1.1k 0.8× | 334 0.5× | 498 1.1× | 192 0.6× | 122 0.7× | 7 | 1.2k | ||
| José María Viéitez Spain | 14 | 1.1k 0.8× | 290 0.4× | 563 1.2× | 132 0.4× | 219 1.2× | 52 | 1.4k | ||
| Cyril Hatem France | 4 | 823 0.6× | 657 1.0× | 238 0.5× | 365 1.1× | 180 1.0× | 5 | 1.3k | ||
| Eugenio Marcuello Spain | 17 | 1.4k 1.1× | 227 0.3× | 385 0.8× | 451 1.3× | 233 1.2× | 33 | 1.6k | ||
| R Castan France | 4 | 829 0.6× | 288 0.4× | 392 0.8× | 117 0.3× | 200 1.1× | 6 | 1.0k | ||
| M. E. Vega-Villegas Spain | 9 | 951 0.7× | 226 0.3× | 562 1.2× | 274 0.8× | 152 0.8× | 17 | 1.2k | ||
| W. Evangelista Italy | 4 | 849 0.6× | 424 0.6× | 303 0.6× | 239 0.7× | 71 0.4× | 7 | 939 |
Countries citing papers authored by E. Pfanner
Since
Specialization
Citations
This map shows the geographic impact of E. Pfanner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Pfanner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Pfanner more than expected).
Fields of papers citing papers by E. Pfanner
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by E. Pfanner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Pfanner. The network helps show where E. Pfanner may publish in the future.
Co-authorship network of co-authors of E. Pfanner
This figure shows the co-authorship network connecting the top 25 collaborators of E. Pfanner. A scholar is included among the top collaborators of E. Pfanner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Pfanner. E. Pfanner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Antoniotti, Carlotta, Federica Marmorino, Marzia Pennati, et al.. (2017). Circulating angiogenesis-related markers as predictors of benefit from regorafenib in metastatic colorectal cancer (mCRC) patients (pts). Annals of Oncology. 28. vi4–vi4.
2.
Salvadori, B., Maria A. Caligo, Andrea Fontana, et al.. (2015). Inherited mutations in breast cancer susceptibility genes among a triple negative breast cancer cohort unselected for family history of breast cancer. Annals of Oncology. 26. vi18–vi18.
3.
Loupakis, Fotios, Chiara Cremolini, Lisa Salvatore, et al.. (2013). FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. European Journal of Cancer. 50(1). 57–63.
4.
Fornaro, Lorenzo, Gianluca Masi, Fotios Loupakis, et al.. (2008). A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology. 63(5). 965–969.
5.
Falcone, Alfredo, Sergio Ricci, I. Brunetti, et al.. (2007). Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest. Journal of Clinical Oncology. 25(13). 1670–1676.
6.
Masi, Gianluca, Fotios Loupakis, Giacomo Giulio Baldi, et al.. (2007). The combination of capecitabine (C), irinotecan (I) and oxaliplatin (O) (XELOXIRI) as first line treatment of metastatic colorectal cancer (MCRC): Preliminary results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.). Journal of Clinical Oncology. 25(18_suppl). 4096–4096.
7.
Masi, Gianluca, Fotios Loupakis, Andrea Antonuzzo, et al.. (2007). 3063 POSTER Capecitabine (C), in combination with irinotecan (I) and oxaliplatin (O) (XELOXIRI) as first-line treatment of metastatic colorectal cancer (MCRC): results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.). European Journal of Cancer Supplements. 5(4). 255–255.
8.
Masi, Gianluca, Samanta Cupini, Lorenzo Marcucci, et al.. (2005). Treatment with 5-Fluorouracil/Folinic Acid, Oxaliplatin, and Irinotecan Enables Surgical Resection of Metastases in Patients With Initially Unresectable Metastatic Colorectal Cancer. Annals of Surgical Oncology. 13(1). 58–65.
9.
Allegrini, Giacomo, Alfredo Falcone, R. Di Marsico, et al.. (2004). 5-Fluorouracil Administered as a 48-Hour Semiintermittent Infusion in Combination With Leucovorin, Cisplatin and Epirubicin. American Journal of Clinical Oncology. 27(1). 101–105.
10.
Falcone, Alfredo, Giacomo Allegrini, Gianluca Masi, et al.. (2001). 5-Fluorouracil Administered as a 48-Hour Chronomodulated Infusion in Combination with Leucovorin and Cisplatin: A Randomized Phase II Study in Metastatic Colorectal Cancer. Oncology. 61(1). 28–35.
11.
Lencioni, Monica, Alfredo Falcone, Giacomo Allegrini, et al.. (2000). Oral Doxifluridine in Advanced Hepatocellular Carcinoma: A Phase II Study. Oncology. 59(3). 204–209.
12.
Falcone, Alfredo, Giacomo Allegrini, Monica Lencioni, et al.. (1999). Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: a phase II study. Cancer Chemotherapy and Pharmacology. 44(2). 159–163.
13.
Falcone, Alfredo, Giacomo Allegrini, Andrea Antonuzzo, et al.. (1999). Infusions of Fluorouracil and Leucovorin: Effects of the Timing and Semi-Intermittency of Drug Delivery. Oncology. 57(3). 195–201.
14.
Falcone, Alfredo, Monica Lencioni, I. Brunetti, et al.. (1997). Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Annals of Oncology. 8(6). 539–545.
15.
Falcone, Alfredo, E. Pfanner, Serafino Ricci, et al.. (1996). Treatment of metastatic renal cell carcinomawith constant-rate floxuridine infusion plus recombinant alpha 2b-interferon. Annals of Oncology.
16.
Baldini, Editta, Carmelo Tibaldi, E. Pfanner, et al.. (1996). Phase II Study of Oral Doxifluridine in Elderly Patients with Advanced Non-Small-Cell Lung Cancer. American Journal of Clinical Oncology. 19(6). 592–594.
17.
Falcone, Alfredo, E. Pfanner, Serafino Ricci, et al.. (1996). Treatment of metastatic renal cell carcinoma with constant-rate floxuridine infusion plus recombinant α2b-interferon. Annals of Oncology. 7(6). 601–605.
18.
Falcone, Alfredo, Rita Danesi, E. Pfanner, et al.. (1996). Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients.. Journal of Clinical Oncology. 14(3). 729–736.
19.
Falcone, Alfredo, E. Pfanner, Romano Danesi, et al.. (1995). Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II Study. Cancer. 75(2). 440–443.
20.
Falcone, Alfredo, E. Pfanner, Serafino Ricci, et al.. (1994). Oral doxifluridine in elderly patients with metastatic colorectal cancer: A multicenter phase II study. Annals of Oncology. 5(8). 760–762.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by M. Andreuccetti Breakdown of academic impact, for papers by H. Kröning Breakdown of academic impact, for papers by S. Vitello Breakdown of academic impact, for papers by Yousif Abubakr Breakdown of academic impact, for papers by José María Viéitez Breakdown of academic impact, for papers by Cyril Hatem Breakdown of academic impact, for papers by Eugenio Marcuello Breakdown of academic impact, for papers by R Castan Breakdown of academic impact, for papers by M. E. Vega-Villegas Breakdown of academic impact, for papers by W. Evangelista